September 20, 2014 8:59 AM ET

Pharmaceuticals

Company Overview of PsiOxus Therapeutics, Ltd.

Company Overview

PsiOxus Therapeutics, Ltd., a biotechnology company, develops novel therapeutics that address cancer and other clinically unmet diseases. The company provides MT-102, a dual action anabolic catabolic transforming agent for the treatment of cancer cachexia and sarcopenia; and ColoAd1, a chimeric oncolytic virus for the systemic treatment of metastatic cancer. It also offers PolySTAR, a research phase vaccine platform that combines recombinant viral vectors with polymers to shield them from the immune system; and PolyMAP, a research phase adjuvant and immunotherapeutic platform that combines polymers with synthetic adjuvants for immunogenicity. PsiOxus Therapeutics, Ltd. was formerly known as ...

154B Milton Park

Abingdon,  OX14 4SD

United Kingdom

Founded in 2006

Phone:

44 1235 835 328

Fax:

44 1869 238 001

Key Executives for PsiOxus Therapeutics, Ltd.

Chief Executive Officer and Director
Founder and Member of Scientific Advisory Board
Finance Director
Chief Operating Officer
Vice President of Pharmaceutical Development
Compensation as of Fiscal Year 2014.

PsiOxus Therapeutics, Ltd. Key Developments

PsiOxus Therapeutics Ltd. Initiates 'OCTAVE' Ovarian Cancer Study for Oncolytic Vaccine Enadenotucirev

PsiOxus Therapeutics Ltd. announced the first dosing of a patient in the OCTAVE (Ovarian Cancer Treated with Adeno Vaccine Enadenotucirev) study. OCTAVE is a phase I/II clinical trial to assess the safety and efficacy of its oncolytic vaccine enadenotucirev (previously known as ColoAd1) in platinum-resistant ovarian cancer patients at multiple UK cancer centres beginning this month. Enadenotucirev has shown potent, broad-spectrum, anti-cancer activity pre-clinically and is also in phase I/II clinical trials in patients with colorectal tumours. The OCTAVE study will examine the safety, tolerability, pharmacokinetics and efficacy of administering the vaccine directly into the abdomen of cancer patients, where ovarian cancer tends to recur (a process known as intra-peritoneal or IP delivery). The phase I component of the study will determine the dose of enadenotucirev to be used alone or in combination with paclitaxel. The phase II component will be an open label dose expansion of the combination regimen of enadenotucirev and paclitaxel to determine whether this combination has a risk benefit profile that supports further investigation in the treatment of patients with platinum-resistant epithelial ovarian cancer. Enadenotucirev was originally developed using a directed evolution process, with the aim of generating an entirely novel virus with optimised cancer-lytic properties. It has been shown to have little or no activity in normal cells whilst keeping a very high level of anti-cancer potency. As well as assessing how effective intraperitoneal enadenotucirev is for treating ovarian cancer, PsiOxus is also carrying out clinical studies evaluating its safety and efficacy via intravenous injection in patients with colorectal cancer. The phase I/II EVOLVE study (EValuating OncoLytic Vaccine Efficacy) is currently underway and has shown some promising early results.

PsiOxus Therapeutics Announces Positive Study Results of Oncolytic Vaccine Enadenotucirev

PsiOxus Therapeutics, Ltd. announced that updates for its on-going international multicentre clinical program of the oncolytic vaccine enadenotucirev (previously known as ColoAd1) were presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Enadenotucirev is an oncolytic Ad11/Ad3 chimeric group B adenovirus that has previously been shown to selectively destroy metastatic solid tumours at low concentrations in pre-clinical models. The EVOLVE (EValuating OncoLytic Vaccine Efficacy) trial is a phase I/II trial of intravenous administration of enadenotucirev to patients with epithelial cancers. Dr. Emiliano Calvo from START Madrid, Centro Integral Oncológico Clara Campal, Hospital Madrid, Spain, presented A Phase I Study of Enadenotucirev, an Oncolytic A11/Ad3 Chimeric Group B Adenovirus, Administered Intravenously in Patients with Metastatic Epithelial Tumours, which evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of enadenotucirev. In this study, enadenotucirev was delivered intravenously to end stage cancer patients. Tumour origins in these patients included colorectal, parotid, oropharynx, liver, stomach, gall bladder and breast. This is the first reported clinical study where live replicating oncolytic virus has been recovered directly from the blood stream of cancer patients. This confirms previously published pre-clinical data showing that unlike other viruses, enadenotucirev is not inactivated by antibodies or other human blood constituents.

PsiOxus Therapeutics Presents at BioTrinity 2014 - European Biopartnering and Investment Conference, May-12-2014

PsiOxus Therapeutics Presents at BioTrinity 2014 - European Biopartnering and Investment Conference, May-12-2014 . Venue: London, United Kingdom.

Similar Private Companies By Industry

Company Name Region
Natures Aid Ltd Europe
Avillion LLP Europe
Giantcode Corporation PLC Europe
Antiva Therapeutics Limited Europe
Speciality European Pharma Limited Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PsiOxus Therapeutics, Ltd., please visit www.psioxus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.